NewsScientists discover a 'supermolecule' that fights more than 300 types of antibiotic-resistant...

    Scientists discover a ‘supermolecule’ that fights more than 300 types of antibiotic-resistant bacteria

    Fabycin could be used to combat persistent urinary tract, lung, and even bloodstream infections caused by gram-negative bacteria.

    An international team of researchers recently published a study in the journal ACS Central Science in which they claim to have discovered a new molecule capable of dealing with hundreds of types of bacteria that have become resistant to drugs.

    denominated fabycinthis molecule could be used to combat persistent infections of the urinary tract, lungs and even the bloodstream caused by bacteria gram negativegenerally difficult to eradicate with known antibiotics because they have a protective outer membrane that acts as a shield against harmful substances.

    Read Also:   "I don't trust you either": the controversial response of the Secretary of the Interior in Mexico to the mother of a missing person

    “Genomic studies and experiments with permeability-deficient strains have revealed a variety of biological targets that may be involved in killing gram-negative bacteria,” the researchers write. “Nevertheless, the formidable outer membrane and the promiscuous expulsion pumps of these pathogens prevent many candidate antibiotics from achieving these targets.”

    Scientists develop a new class of synthetic antibiotics that could save millions of lives

    The scientists stress that fabimycin overcomes these problems by passing through the outer layer of the cell, evading protective mechanisms. In addition, this molecule prevents the elimination of commensal bacteria—those that are beneficial to the human body—another problem that many current treatments present.

    Read Also:   Ukraine News: Ukraine is investigating nearly 26,000 war crimes cases

    In laboratory tests, fabimycin had an effect on more than 300 types of drug-resistant bacteria and reduced levels of harmful bacteria in mice with pneumonia or urinary tract infections.

    “Given the promising activity of fabimicin in mouse models of infection and the encouraging data that fabimicin is much more stable in human plasma […] it is reasonable to believe that its efficacy may improve as it is used to treat infections in higher organisms”, add the researchers, who conclude that “the potency” of this molecule, “combined with the apparent lack of pre-existing resistance”, constitute “a bode well”.

    Read Also:   A third attempt to impeach President Pedro Castillo takes shape in Peru

    For now, the team will focus on preparing fabymycin for use in human trials so it can eventually be incorporated into widely used drugs.

    Source: RT

    This post is posted by Awutar staff members. Awutar is a global multimedia website. It serves as a source of News, Business, Opinion, Analysis, Sports, Health, Fitness, Technology, Education, Travel, and More. If you want to get in touch with us write via: [email protected]


    Please enter your comment!
    Please enter your name here

    eleven + 12 =

    Subscribe & Get Latest News